Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

The company is set to receive a significant upfront payment of $1.4 billion from Roche in the second quarter of 2025, reflecting a major collaborative effort. Zealand Pharma’s cash position ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

The company is set to receive a significant upfront payment of $1.4 billion from Roche (LON:0QQ6) in the second quarter of 2025, reflecting a major collaborative effort. Zealand Pharma’s cash position ...

In March, Roche committed up to US$5.3 billion to Zealand Pharma to work together on the phase II amylin analogue petrelintide, for example, and AbbVie committed up to $2.3 billion to partner with ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...

approved for SBS since 2012 in the US – and experimental-stage rivals like Zealand Pharma’s glepaglutide, which reported phase 3 results in SBS last year. SBS is a rare condition in which ...